Adult: 2.5-5 mg once daily. Child: 6 months-5 years 1.25 mg once daily. 6-11 years 2.5 mg once daily in the evening. >12 years Same as adult dose.
Patients undergoing dialysis: Contraindicated.
2.5 mg once twice weekly.
2.5 mg every other
2.5 mg once daily.
May be taken with or without food.
ESRD (CrCl < 10 mL/min) or undergoing haemodialysis.
Patient with increased risk of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia), epileptic patients and at risk of convulsion. Children. Mild to moderate renal impairment. Pregnancy and lactation.
Significant: CNS depression, rebound pruritus. Ear and labyrinth disorders: Otitis media. Gastrointestinal disorders: Dry mouth, diarrhoea, vomiting, constipation, abdominal pain. General disorders and administration site conditions: Fatigue, asthenia, pyrexia. Nervous system disorders: Headache. Psychiatric disorders: Sleep disorder, somnolence. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, pharyngitis, cough. Vascular disorders: Epistaxis.
This drug may cause somnolence, fatigue and asthenia, if affected, do not drive or operate machinery.
Monitor renal function.
Symptoms: Drowsiness; agitation, restlessness (children). Management: Symptomatic and supportive. Gastric lavage may be considered shortly following ingestion.
Possible additive adverse CNS effects with CNS depressants (e.g. sedatives, tranquilizers).
Concomitant use with alcohol may result in additive CNS depression.
Description: Levocetirizine, an antihistamine and is an active enantiomer of cetirizine. Its binding affinity to H1-receptor is twice than cetirizine. It selectively competes for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. Onset: 1 hour. Duration: 24 hours. Pharmacokinetics: Absorption: Rapid and extensive oral absorption. Time to peak plasma concentration: 0.9 hours. Distribution: Volume of distribution: Approx 0.4 L/kg. Plasma protein binding: 91-92%. Metabolism: Metabolised by aromatic oxidation, N- and O-dealkylation (via CYPA4) and taurine conjugation. Excretion: Mainly via urine (85.4%); faeces (12.9%). Elimination half-life: Approx 8-9 hours.
R06AE09 - levocetirizine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Anon. Levocetirizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/06/2019.Anon. Levocetirizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/01/2014.Buckingham R (ed). Levocetirizine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/06/2019.Joint Formulary Committee. Levocetirizine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/06/2019.Levocetirizine Dihydrochloride Solution (Camber Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 11/06/2019.Levocetirizine Dihydrochloride Tablet, Film Coated (Micro Labs Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 11/06/2019.Levocetirizine Syrup (Unimed Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/06/2019.Levocetirizine Tablet (Unimed Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/06/2019.McEvoy GK, Snow EK, Miller J et al (eds). Levocetirizine Dihydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 21/01/2014.Xyzal (UCB Farchim S.A.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 21/01/2014.Xyzal Oral Solution and Tablets. U.S. FDA. https://www.fda.gov/. Accessed 21/01/2014.